Polyarthritis and anemia in a hemodialysis patient: Systemic lupus erythematosus following treatment with Interferon α

Clinical Nephrology

Volumn 73, Issue 4, 2010, Pages 318-320

  Touzot, M ^a,b   Touzot, F ^a   Galicier, L ^a   Ripault, M P ^a   Peraldi, M N ^a   Glotz, D ^a   Pillebout, E ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

End stage renal disease; Hepatitis C; Interferon ; Systemic lupus erythematosus

Indexed keywords

ACEBUTOLOL; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD PRESSURE; CASE REPORT; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMODIALYSIS; HEPATITIS C; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; MALE; POLYARTHRITIS; RETICULOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 77950806389     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp73318     Document Type: Article

References (10)

1. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmunedisease antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002; 32: 163-173. (Pubitemid 36043715)
2. Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitisCvirus infection.NEngl J Med. 2002; 347: 975-982.
3. Fukuyama S et al. Systemic lupus erythematosus after α-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol. 2000; 95: 310-312. (Pubitemid 30041583)
4. Lodato F et al. Systemic lupus erythematosus following virological response to peginterferon α-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol. 2006; 12: 4253-4255. (Pubitemid 44376915)
5. Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol. 2008; 14: 166-168.
6. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982; 23; 216: 429-431.
7. Kirou KA et al. Activation of the interferon-?pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52: 1491-1503.
8. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med. 2003; 197: 777-788. (Pubitemid 36350872)
9. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol. 2005; 174: 2499-2506. (Pubitemid 40279662)
10. Okano K, Yumura W, Nihei H. Analysis of lupus activity in end-stage renal disease treated by hemodialysis Intern Med. 2001; 40: 598-602. (Pubitemid 33611892)